Timothy Barberich
Chairman bei TSCAN THERAPEUTICS, INC.
Vermögen: 796 271 $ am 31.03.2024
Profil
Timothy Joseph Barberich was the founder of Sumitomo Pharma America, Inc., founded in 1984, where he served as Chairman from 2008 to 2009.
He was also the founder of Neurovance, Inc., founded in 2010, where he was a Director from 2010 to 2016.
Additionally, he is the founder of MirImmune, Inc., founded in 2015, where he currently serves as a Director.
Mr. Barberich's current job(s) include being the Chairman & Chief Executive Officer at Bionevia Pharmaceuticals, Inc. since 2008, Chairman at TScan Therapeutics, Inc. since 2019, Director at Gemin X Pharmaceuticals Canada, Inc., and Director at Newcastle Holdings Ltd.His former job(s) include being the Chairman at EMD Millipore Corp., Director at Point Therapeutics, Inc. from 1993 to 2008, Director at BioSphere Medical, Inc., Independent Director at Inotek Pharmaceuticals Corp.
from 2016 to 2017, Independent Non-Executive Director at GI Dynamics, Inc. from 2011 to 2021, Director at DARA BioSciences, Inc., Non-Executive Director at Heartware Pty Ltd., Director at Resolvyx Pharmaceuticals, Inc. in 2009, Director at Gemin X Pharmaceuticals US, Inc. from 2007 to 2011, Director at Boston Medical Center, Director at Pharmaceutical Research & Manufacturers of America, Independent Director at Tokai Pharmaceuticals, Inc. from 2009 to 2017, Director at HeartWare, Inc. from 2008 to 2016, Non-Executive Director at HeartWare International LLC from 2008 to 2016, Director at Euthymics Bioscience, Inc., Independent Director at Verastem, Inc. from 2014 to 2022, and Independent Director at Frequency Therapeutics, Inc. from 2016 to 2022.
Mr. Barberich's education includes an undergraduate degree from King's College (Pennsylvania) in 1969 and an undergraduate degree from Rutgers University, Camden in 1972.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
TSCAN THERAPEUTICS, INC.
0,23% | 19.12.2023 | 100 286 ( 0,23% ) | 796 271 $ | 31.03.2024 |
Aktive Positionen von Timothy Barberich
| Unternehmen | Position | Beginn |
|---|---|---|
| TSCAN THERAPEUTICS, INC. | Chairman | 01.03.2021 |
| Newcastle Holdings Ltd. | Director/Board Member | - |
MirImmune, Inc.
 MirImmune, Inc. BiotechnologyHealth Technology MirImmune, Inc. is a biopharmaceutical company that develops new generation immunotherapies for cancer. It combines two approaches to cancer treatment: immune checkpoint inhibition and cell-based immunotherapies. The company was founded by Alexey V. Eliseev, Alexey Wolfson, and Timothy Joseph Barberich on May 18, 2015 and is headquartered in Boston, MA. | Founder | 18.05.2015 |
Gemin X Pharmaceuticals Canada, Inc.
 Gemin X Pharmaceuticals Canada, Inc. Pharmaceuticals: MajorHealth Technology Part of Cephalon, Inc., Gemin X Pharmaceuticals Canada, Inc. is a private company based in Montréal, Canada. | Director/Board Member | - |
Bionevia Pharmaceuticals, Inc.
 Bionevia Pharmaceuticals, Inc. Hospital/Nursing ManagementHealth Services Bionevia Pharmaceuticals, Inc. operates as a chronic disease hospital. Timothy Joseph Barberich has been the CEO of the American company since 2008. | Chief Executive Officer | 01.01.2014 |
Ehemalige bekannte Positionen von Timothy Barberich
| Unternehmen | Position | Ende |
|---|---|---|
| VERASTEM, INC. | Director/Board Member | 31.03.2022 |
| GI DYNAMICS, INC. | Director/Board Member | 01.01.2021 |
Tokai Pharmaceuticals, Inc.
 Tokai Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tokai Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel proprietary therapies for the treatment of prostate cancer and hormonally driven diseases. The company was founded by Joseph A. Yanchik, Gregory L. Verdine, and Seth L. Harrison on March 26, 2004 and is headquartered in Boston, MA. | Director/Board Member | 01.01.2017 |
Inotek Pharmaceuticals Corp.
 Inotek Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Inotek Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. The company's product candidate includes Trabodenoson, an adenosine mimetic that has completed Phase II clinical trials for lowering IOP by restoring the eye's natural pressure control mechanism. It is also developing Trabodenoson plus Latanoprost, a prostaglandin analogue that has completed Phase II clinical trials for use in patients with inadequate responses to treatment with latanoprost; and Trabodenoson monotherapy for the treatment of optic nerve neuropathy. Inotek Pharmaceuticals was founded on July 7, 1999 by Csaba Szabo and Andrew L. Salzman and is headquartered in Lexington, MA. | Director/Board Member | 01.01.2017 |
| ░░░░░░░░░ ░░░░░░░░░░░░░ ░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
Ausbildung von Timothy Barberich
| King's College (Pennsylvania) | Undergraduate Degree |
| Rutgers University, Camden | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| VERASTEM, INC. | Health Technology |
| TSCAN THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 22 |
|---|---|
EMD Millipore Corp.
 EMD Millipore Corp. Miscellaneous Commercial ServicesCommercial Services EMD Millipore Corp. engages in the provision of laboratory materials, technologies, and services to the life science industry. The company was founded by Jack Bush in 1954 and is headquartered in Burlington, MA. | Commercial Services |
Sumitomo Pharma America, Inc.
 Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 2010 and is headquartered in Marlborough, MA. | Health Technology |
Point Therapeutics, Inc.
 Point Therapeutics, Inc. BiotechnologyHealth Technology Point Therapeutics, Inc. develops drugs for the treatment of cancer and blood cell disorders. The company's PT-100 (talabostat) treats anemia and neutropenia (low levels of white blood cells), which can be caused by diseases or medical treatments, such as chemotherapy. The drugs stimulate production of proteins that build up the body's immune system against malignant tumors. Point Therapeutics, Inc. is located in Boston, MA. | Health Technology |
BioSphere Medical, Inc.
 BioSphere Medical, Inc. Medical SpecialtiesHealth Technology BioSphere Medical, Inc. develops, manufactures and markets microsphere technology to medical applications. The company uses microsphere technology to develop its products for medical applications using embolotherapy techniques. It offers Embosphere Microspheres for uterine fibroids, hypervascularized tumors and other arteriovenous malformations, EmboGold Microspheres for Hypervascularized tumors and arteriovenous malformations, EmboCath Infusion Catheter and Segway Guidewire for peripheral embolization procedures and HepaSphere Microspheres for liver cancer. The company was founded in 1993 and is headquartered in Rockland, MA. | Health Technology |
Inotek Pharmaceuticals Corp.
Inotek Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Inotek Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. The company's product candidate includes Trabodenoson, an adenosine mimetic that has completed Phase II clinical trials for lowering IOP by restoring the eye's natural pressure control mechanism. It is also developing Trabodenoson plus Latanoprost, a prostaglandin analogue that has completed Phase II clinical trials for use in patients with inadequate responses to treatment with latanoprost; and Trabodenoson monotherapy for the treatment of optic nerve neuropathy. Inotek Pharmaceuticals was founded on July 7, 1999 by Csaba Szabo and Andrew L. Salzman and is headquartered in Lexington, MA. | Health Technology |
GI Dynamics, Inc.
 GI Dynamics, Inc. Medical SpecialtiesHealth Technology GI Dynamics, Inc. engages in the development and commercialization of a medical device system intended for treatment of patients with type 2 diabetes and reduction of obesity. Its pipeline product is EndoBarrier, an endoscopically delivered medical device intended to help restore healthy blood sugar levels and reduce weight. The company was founded by Andy Levine on March 24, 2003 and is headquartered in Boston, MA. | Health Technology |
DARA BioSciences, Inc. /Old/
 DARA BioSciences, Inc. /Old/ Pharmaceuticals: MajorHealth Technology DARA BioSciences, Inc. develops therapeutic and medical technologies and devices. It also provides treatment for metabolic diseases and central nervous system disorders . The company was founded by Steve Gorlin in July, 2002 and is headquartered in Raleigh, NC. | Health Technology |
Heartware Pty Ltd.
 Heartware Pty Ltd. Medical SpecialtiesHealth Technology HeartWare Pty. Ltd. develops and manufactures implantable circulatory assist devices. Its devices are used in treating patients with congestive heart failure. The company is headquartered in Sydney, Australia. | Health Technology |
Resolvyx Pharmaceuticals, Inc.
 Resolvyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Resolvyx Pharmaceuticals, Inc. discovers and develops therapeutics for inflammatory diseases. Its products include RX-10001, RX-10045 and RX-20001. The firm's focus is to develop a new class of medicines called Resolvins for the treatment of a range of ophthalmic diseases. The company was founded by Daniel Goodman, Charles N. Serhan, Per Gjorstrup and Thomas E. Van Dyke in June 20, 2001 and is headquartered in Cambridge, MA. | Health Technology |
Neurovance, Inc.
 Neurovance, Inc. Miscellaneous Commercial ServicesCommercial Services Neurovance, Inc. operates as a a biopharmaceutical company. It develops treatments for central nervous system disorders. The company was founded by Anthony McKinney and Franklin P. Bymaster in 2011 and is headquartered in Cambridge, MA. | Commercial Services |
Gemin X Pharmaceuticals US, Inc.
 Gemin X Pharmaceuticals US, Inc. BiotechnologyHealth Technology Gemin X Pharmaceuticals US Inc. is engaged in the development of cancer therapeutics. It offers mimetic and telomere capping programs, as well as screening, medicinal chemistry, and preclinical development services. The company was founded by Gordon C. Shore in 1998 and is headquartered in Malvern, PA. | Health Technology |
Boston Medical Center
 Boston Medical Center Hospital/Nursing ManagementHealth Services Boston Medical Center provides healthcare services. It provides a spectrum of pediatric and adult care services from primary to family medicine specialty care. The hospital is established in July 1996 and is headquartered in Boston, MA | Health Services |
Pharmaceutical Research & Manufacturers of America
 Pharmaceutical Research & Manufacturers of America Pharmaceuticals: MajorHealth Technology Pharmaceutical Research & Manufacturers of America provides pharmaceutical research and biotechnology services. It represents the country’s biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives. The company was founded in 1958 and is headquartered Washington, DC. | Health Technology |
Tokai Pharmaceuticals, Inc.
Tokai Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tokai Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel proprietary therapies for the treatment of prostate cancer and hormonally driven diseases. The company was founded by Joseph A. Yanchik, Gregory L. Verdine, and Seth L. Harrison on March 26, 2004 and is headquartered in Boston, MA. | Health Technology |
HeartWare, Inc.
 HeartWare, Inc. Medical SpecialtiesHealth Technology HeartWare, Inc. manufactures electro medical and electrotherapeutic apparatus. The company develops implantable circulatory assist devices, which are used in treating patients with congestive heart failure problems. The company was established in 2003 and is headquartered in Miramar, FL | Health Technology |
Bionevia Pharmaceuticals, Inc.
Bionevia Pharmaceuticals, Inc. Hospital/Nursing ManagementHealth Services Bionevia Pharmaceuticals, Inc. operates as a chronic disease hospital. Timothy Joseph Barberich has been the CEO of the American company since 2008. | Health Services |
HeartWare International LLC
 HeartWare International LLC Medical SpecialtiesHealth Technology HeartWare International LLC is a medical device company, which engaged in the development and manufacturing of miniaturized implantable heart pumps or ventricular assist devices to treat patients suffering from advanced heart failure. The company was founded on July 29, 2008 and is headquartered in Framingham, MA. | Health Technology |
Euthymics Bioscience, Inc.
 Euthymics Bioscience, Inc. Miscellaneous Commercial ServicesCommercial Services Euthymics Bioscience, Inc. develops a novel medicine for alcohol use disorder (AUD) and smoking cessation. It engages in developing a medicine for central nervous system disorders of significant unmet medical need, including major depressive disorder (MDD) and alcohol use disorder (AUD). The firm provides Amitifadine, an antidepressant for major depressive disorder. The firm focuses on the modulation of neurotransmitters, including serotonin (5-HT), norepinephrine (NE), and dopamine (DA). The company was founded by Anthony A. McKinney and Franklin P. Bymaster in 2009 and is headquartered in Cambridge, MA. | Commercial Services |
Gemin X Pharmaceuticals Canada, Inc.
Gemin X Pharmaceuticals Canada, Inc. Pharmaceuticals: MajorHealth Technology Part of Cephalon, Inc., Gemin X Pharmaceuticals Canada, Inc. is a private company based in Montréal, Canada. | Health Technology |
MirImmune, Inc.
MirImmune, Inc. BiotechnologyHealth Technology MirImmune, Inc. is a biopharmaceutical company that develops new generation immunotherapies for cancer. It combines two approaches to cancer treatment: immune checkpoint inhibition and cell-based immunotherapies. The company was founded by Alexey V. Eliseev, Alexey Wolfson, and Timothy Joseph Barberich on May 18, 2015 and is headquartered in Boston, MA. | Health Technology |
| Newcastle Holdings Ltd. | |
Frequency Therapeutics, Inc.
 Frequency Therapeutics, Inc. BiotechnologyHealth Technology Frequency Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the business of developing therapeutics to activate a person's innate regenerative potential to restore function. The firm is also involved in creating and commercializing therapeutics to potentially transform the lives of individuals by repairing or reversing damage done to cells, tissue, and organs. The company was founded by Robert S. Langer, David L. Lucchino, Christopher R. Loosey, and Will J. McLean on November 13, 2014 and is headquartered in Lexington, MA. | Health Technology |
